{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:50:02Z","timestamp":1780447802572,"version":"3.54.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473253"],"award-info":[{"award-number":["82473253"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.19094-44"],"award-info":[{"award-number":["320.6750.19094-44"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373056"],"award-info":[{"award-number":["82373056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing life Qasis Public Service Center","award":["cphcf-2022-024"],"award-info":[{"award-number":["cphcf-2022-024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trophoblast cell-surface antigen 2 (Trop2), a transmembrane glycoprotein overexpressed in multiple cancers, plays crucial roles in tumor progression and therapy resistance, yet its expression patterns and clinical significance in digestive cancers remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed a consecutive cohort of 2370 patients with histologically confirmed digestive cancers (804 gastric [GC], 1,384 colorectal [CRC], and 182 pancreatic cancers [PC]). Comprehensive clinicopathological data were systematically collected. Trop2 expression was quantitatively evaluated by immunohistochemistry and classified into Trop2-negative, Trop2-low, and Trop2-high based on the product of staining intensity and the proportion of positive tumor cells. Statistical analyses included univariate and multivariate logistic regression were used to identify significant clinicopathological and molecular predictors of Trop2 expression patterns. Univariate and multivariate logistic regression analyses were used to explore the relationship between Trop2 expression status (positive [Trop2 intensity\u2009\u2265\u20092] vs. negative) and various clinicopathological features of different tumor types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Trop2 was widely expressed in digestive cancers, with highest prevalence in PC and GC. Multivariate analysis revealed distinct Trop2 expression patterns in gastrointestinal malignancies. At the pan-cancer level, Trop2 expression significantly correlated with tumor type, (signet ring cell carcinoma) SRCC, vascular invasion (VI) and perineural invasion. Notably, GC showed independent associations with SRCC and intestinal-type Lauren classification; CRC showed VI as the predominant factor associated with Trop2 expression; while PC demonstrated unique correlations with female sex and T1 stage. These findings highlight tumor-type specific regulation of Trop2, providing critical insights for prognostic assessment and targeted therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Trop2 is a promising biomarker for tumor aggressiveness and a potential target for antibody-drug conjugates (ADCs) in digestive cancers, particularly in SRCC-rich, metastatic, and invasive subtypes. These findings provide strong rationale for stratifying patient populations in future clinical investigations of Trop2-directed ADC therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf320","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:28:03Z","timestamp":1760531283000},"source":"Crossref","is-referenced-by-count":2,"title":["Trophoblast cell-surface antigen 2 expression in digestive neoplasms: a promising target for antibody-drug conjugates"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8838-5587","authenticated-orcid":false,"given":"Jinru","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University , Wuhan, Hubei 430071,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology , Wuhan, Hubei 430030,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Cai","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei 430022,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Ding","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine of Lanzhou University , Lanzhou, Hubei 730000,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-9864","authenticated-orcid":false,"given":"Conghua","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University , Wuhan, Hubei 430071,","place":["P.R. China"]},{"name":"Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences , Wuhan, Hubei 420071,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2480-6332","authenticated-orcid":false,"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology , Wuhan, Hubei 430030,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2025112711113991500_oyaf320-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025112711113991500_oyaf320-B2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.trecan.2024.05.001","article-title":"Advancements in combining targeted therapy and immunotherapy for colorectal cancer","volume":"10","author":"Singh","year":"2024","journal-title":"Trends Cancer"},{"key":"2025112711113991500_oyaf320-B3","doi-asserted-by":"publisher","first-page":"705999","DOI":"10.3389\/fimmu.2021.705999","article-title":"Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"2025112711113991500_oyaf320-B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2025112711113991500_oyaf320-B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody-drug conjugates in cancer: Overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"2025112711113991500_oyaf320-B6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2025112711113991500_oyaf320-B7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2025112711113991500_oyaf320-B8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"2025112711113991500_oyaf320-B9","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"2025112711113991500_oyaf320-B10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112711113991500_oyaf320-B11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112711113991500_oyaf320-B12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1186\/s12885-022-10076-7","article-title":"Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer","volume":"22","author":"Jeon","year":"2022","journal-title":"BMC Cancer"},{"key":"2025112711113991500_oyaf320-B13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1477-7819-10-53","article-title":"Significance of EpCAM and TROP2 expression in non-small cell lung cancer","volume":"10","author":"Pak","year":"2012","journal-title":"World J Surg Oncol"},{"key":"2025112711113991500_oyaf320-B14","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2025112711113991500_oyaf320-B15","doi-asserted-by":"publisher","first-page":"e75864","DOI":"10.1371\/journal.pone.0075864","article-title":"Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"2025112711113991500_oyaf320-B16","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3892\/ijmm.2019.4378","article-title":"TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K\/akt signaling pathway","volume":"44","author":"Tang","year":"2019","journal-title":"Int J Mol Med"},{"key":"2025112711113991500_oyaf320-B17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jare.2023.05.012","article-title":"Targeting Trop2 by bruceine D suppresses breast cancer metastasis by blocking Trop2\/\u03b2-catenin positive feedback loop","volume":"58","author":"Tang","year":"2024","journal-title":"J Adv Res"},{"key":"2025112711113991500_oyaf320-B18","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"2025112711113991500_oyaf320-B19","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of advanced Non-Small-Cell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025112711113991500_oyaf320-B20","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1158\/1078-0432","article-title":"Sacituzumab govitecan demonstrates efficacy across tumor trop-2 expression levels in patients with advanced urothelial cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025112711113991500_oyaf320-B21","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025112711113991500_oyaf320-B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody-drug conjugates in solid tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu Rev Med"},{"key":"2025112711113991500_oyaf320-B23","doi-asserted-by":"publisher","first-page":"1495675","DOI":"10.3389\/fimmu.2024.1495675","article-title":"Advances in trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions","volume":"15","author":"Tong","year":"2024","journal-title":"Front Immunol"},{"key":"2025112711113991500_oyaf320-B24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025112711113991500_oyaf320-B25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/modpathol.3801001","article-title":"TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity","volume":"21","author":"Fong","year":"2008","journal-title":"Mod Pathol"},{"key":"2025112711113991500_oyaf320-B26","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40618-023-02245-7","article-title":"Claudin 18.2 expression in digestive neuroendocrine neoplasms: a clinicopathological study","volume":"47","author":"Jiang","year":"2024","journal-title":"J Endocrinol Invest"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf320\/64717749\/oyaf320.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf320\/64717749\/oyaf320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf320\/64717749\/oyaf320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:11:51Z","timestamp":1764259911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf320\/8287638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf320","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,16]]},"article-number":"oyaf320"}}